Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

BACKGROUND: Alectinib, a highly selective, central nervous system (CNS)-active anaplastic lymphoma kinase (ALK) inhibitor, demonstrated promising clinical activity in crizotinib-naïve and crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC). This phase 2 study evaluated the safety an...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Lancet Oncol
मुख्य लेखकों: Shaw, Alice T., Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J., Cetnar, Jeremy, West, Howard, Camidge, D. Ross, Socinski, Mark A., Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H., Borghaei, Hossein, Gold, Kathryn A., Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ignatius Ou, Sai-Hong
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2015
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4752892/
https://ncbi.nlm.nih.gov/pubmed/26708155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00488-X
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन